Cargando…

The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell Lung Cancer and Its Relationship with Prognosis

OBJECTIVE: To explore the effect of combined treatment of PD-1 inhibitor and chemotherapy on the level of peripheral blood T lymphocytes in non-small-cell lung cancer (NSCLC) patients and its relationship with prognosis. METHODS: Retrospective analysis was conducted on 150 NSCLC patients treated in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yun, He, Jianbo, Zhou, Shaozhang, Ning, Ruiling, Zhao, Wenhua, Wang, Huilin, Su, Cuiyun, Jiang, Wei, Zhong, Xiaoning, Yu, Qitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473904/ https://www.ncbi.nlm.nih.gov/pubmed/36118825 http://dx.doi.org/10.1155/2022/1679191

Ejemplares similares

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
por: Chen, Shubin, et al.
Publicado: (2022)

Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR-TKI treatment in advanced NSCLC
por: Jiang, Wei, et al.
Publicado: (2020)

Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Chen, Shubin, et al.
Publicado: (2021)

Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Wenhua, et al.
Publicado: (2021)

STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
por: Su, Cuiyun, et al.
Publicado: (2020)

Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy
por: Yuan, Chengliang, et al.
Publicado: (2022)

Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
por: Yuan, Chengliang, et al.
Publicado: (2021)

Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis
por: Jiang, Wei, et al.
Publicado: (2018)

Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review
por: Zhao, Yun, et al.
Publicado: (2023)

The Association between Pretreatment anemia and Overall Survival in Advanced Non-small Cell lung Cancer: A Retrospective Cohort Study Using Propensity Score Matching
por: Huang, Yucong, et al.
Publicado: (2022)

The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
por: Chen, Shubin, et al.
Publicado: (2023)

Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation
por: Zhou, Shaozhang, et al.
Publicado: (2019)

NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report
por: Wang, Huilin, et al.
Publicado: (2022)

Predictive value of pretreatment albumin‐to‐alkaline phosphatase ratio for overall survival for patients with advanced non‐small cell lung cancer
por: Zhou, Shaozhang, et al.
Publicado: (2020)

Pretreatment plasma d-dimer levels as an independent prognostic factor for overall survival among patients with advanced non-small-cell lung cancer
por: Liu, Qianfei, et al.
Publicado: (2020)

Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer
por: Pan, Mingmei, et al.
Publicado: (2021)

A Retrospective Cohort Study on Pretreated Neutrophil-to-Lymphocyte Ratio and Prognosis of Small Cell Lung Cancer: Evidence of Effect Modification by Chemotherapy Regimen
por: Liu, Feiwen, et al.
Publicado: (2020)

Relationship Between the Expression of PD-1 and CTLA-4 on T Lymphocytes and the Severity and Prognosis of Sepsis
por: Wang, Lang, et al.
Publicado: (2023)

The predictive value of pretreatment haemoglobin-to-red cell distribution width ratio for overall survival of patients with advanced non-small cell lung cancer: a propensity score matching analysis
por: Jiang*, Huiqin, et al.
Publicado: (2021)

Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non‐squamous non‐small cell lung cancer patients
por: Liu, Feiwen, et al.
Publicado: (2023)

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
por: Geng, Ruixuan, et al.
Publicado: (2023)

Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis
por: Li, Xiaomin, et al.
Publicado: (2021)

The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer
por: Chu-Yuan, Hong, et al.
Publicado: (2013)

Prognostic Value of Pretreatment Albumin-to-Alkaline Phosphatase Ratio in Extensive-Disease Small-Cell Lung Cancer: A Retrospective Cohort Study
por: Zhou, Shaozhang, et al.
Publicado: (2020)

The alterations in peripheral lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in hepatocellular carcinoma
por: Xie, Qu, et al.
Publicado: (2023)

Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Potential Predictors of Prognosis in Acute Ischemic Stroke
por: Chen, Cuiping, et al.
Publicado: (2021)

Effect of Peripheral Blood Lymphocytes on Prognosis of Multiple Cancers
por: Zhang, Xiaofang, et al.
Publicado: (2023)

Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer
por: Zgodzinski, Witold, et al.
Publicado: (2018)

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
por: Yuan, Keyu, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
por: Sun, Chenglong, et al.
Publicado: (2020)

Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer
por: WANG, FEN, et al.
Publicado: (2015)

Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy
por: Ma, Xiaolu, et al.
Publicado: (2022)

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis
por: Wu, Yuchen, et al.
Publicado: (2016)

Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer
por: Huang, Xue, et al.
Publicado: (2023)

PD-1 Involvement in Peripheral Blood CD8(+) T Lymphocyte Dysfunction in Patients with Acute-on-chronic Liver Failure
por: Zhou, Xiaoshuang, et al.
Publicado: (2021)

T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer
por: Chen, Tingting, et al.
Publicado: (2022)

Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer
por: Yao, W., et al.
Publicado: (2021)

Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer
por: Wu, Chaorui, et al.
Publicado: (2022)

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
por: Guo, Xiaodi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lueofh4rrt9mprlb8e4893t6jd